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Abstract 
Alzheimer's disease (AD) is the most common form of dementia and the most 
common neurodegenerative disease, with a complex genetic background. Genome 
wide association studies (GWAS) have yielded important new insights into genetic 
mechanisms of AD pathology. Current results unequivocally confirm apolipoprotein E 
(APOE) as a major genetic risk factor for development of late onset AD. Additional 
associations of more than twenty genes have also been identified and replicated in 
subsequent genetic studies. Despite the exciting new GWAS data which have 
emerged in the last few years, it has become clear that common variants within the 
genome cannot fully explain the underlying genetic risk for AD.  Novel approaches 
such as genome-wide analysis of copy number variations (CNV) or low-frequency 
rare functional gene variants may provide additional insight into genetic basis of AD. 
In this review we summarize the findings of eighteen GWAS studies in AD performed 
to date, with an emphasis on potential future developments in the quest for genetic 
risk factors of AD. 
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List of abbreviations: Aβ, β-amyloid; ACAN, aggrecan;  ACE, angiotensin I converting enzyme;  
AD, Alzheimer's disease; APOE, apolipoprotein E; APP, amyloid precursor protein; ARSB, 
Arylsulfatase B;  ATXN1, ataxin 1; BCR, breakpoint cluster region; BIN1, bridging integrator 1; 
BLOC1S3, biogenesis of lysosomal organelles complex-1, subunit 3; CAND1, cullin-associated and 
neddylation-dissociated 1; CH25H, cholesterol 25-hydroxylase; CHRNA7, cholinergic receptor, 
nicotinic, alpha 7;  CHRNB2, cholinergic receptor, nicotinic, beta 2; CHARGE, Cohort for Heart and 
Aging Research in Genomics Epidemiology; CLU, clusterin;  CNV, copy number variations; CNTN5, 
contactin 5; CR1, complement component (3b/4b) receptor 1; CST3, cystatin C; CTSS, cathepsin S; 
DISC1, disrupted in schizophrenia 1; ECT, entorhinal cortex thickness; EBF3, early B-cell factor 3; 
EFNA5, ephrin-A5; FAM113B, family with sequence similarity 113, member B;  FAM63A, family with 
sequence similarity 63, member A; FDR, false discovery rate;  GAB2, GRB2-associated binding 
protein 2; GALP, Galanine and galanine-like peptides; GRB2, growth factor receptor bound protein;; 
GWAS, Genome wide association studies; KEGG, Kyoto Encyclopedia of Genes and Genomes;; LD, 
linkage disequilibrium; LMNA, , lamin A/C; LRAT, lecithin retinol acyltransferase;  MAGI2, membrane 
associated guanylate kinase, WW and PDZ domain containing 2; MAPT, microtubule-associated 
protein tau;  MARK4, MAP/microtubule affinity-regulating kinase 4; MRI, magnetic resonance imaging; 
MYH13, myosin, heavy chain 13;  MTHFD1L, methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like; PCK1, phosphoenolpyruvate carboxykinase 1; PCDH11X, protocadherin 11 X-
linked;  PGBD1, piggyBac transposable element derived 1; PICALM, phosphatidylinositol binding 
clathrin assembly protein; PRNP, prion protein; PRUNE2, prune homolog 2; PSEN, presenilin; QT, 
quantitative trait; RNF220, ring finger protein 220; SNP, single nucleotide polymorphism;  SORL1, 
sortilin-related receptor; TF, transferrin;  THF, tetrahydrofolate; TNK1, tyrosine kinase, non receptor 1; 
TOMM40, translocase of outer mitochondrial membrane 40 homolog; TPT, temporal pole cortex 
thickness;  TRAK1, trafficking protein, kinesin binding 1; TRPC4AP, transient receptor potential cation 
channel, subfamily C, member 4 associated protein;  UBD, ubiquitin D; UTP20, UTP20, small subunit 
(SSU) processome component, homolog; WML, white matter lesion volume;  ZNF224, zinc finger 
protein 224 
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Introduction 
 
Alzheimer's disease (AD) is the most common form of dementia and the most 
common neurodegenerative disease. The estimated prevalence of the disease in 
2006 was approximately 27 million people, with the highest number of patients 
present in the regions of Asia and Europe (Brookmeyer et al., 2007). The number of 
patients with dementia is increasing by roughly 4.5 million people annually (Ferri et 
al., 2005), and is projected to reach more than 115 million by the year 2050 (Prince 
and Jackson 2009).  
The disease is characterized histopathologically by the accumulation of β-amyloid 
plaques and neurofibrillary tangles, leading to progressive neuronal and synaptic loss 
in the limbic and association areas of cortex and in subcortical nuclei (Selkoe 1991; 
Chertkow et al., 2001; Tiraboschi et al., 2004; Takashima, 2009). The AD patients 
exhibit a plethora of symptoms related chiefly to progressive cognitive and functional 
decline (Waldemar et al., 2007).  The pathogenesis of AD still remains not fully 
elucidated, but deposition of β-amyloid (Aβ) 1-42 derived from amyloid precursor 
protein (APP), appears to be a key element contributing to oxidative stress, tau 
pathology, mitochondrial insufficiency and synaptic failure. Aβ, which is the major 
component of senile plaques, is cleaved from APP first by β-secretase, and then by 
the γ-secretase. 
Genetic background of the disease is heterogeneous and complex, without a 
straightforward mode of inheritance. The patients can be divided in two major forms 
of the disease, namely those with an early age of onset, usually below 65 years of 
age, and patients with the late onset AD (LOAD), typically well beyond 65 years. The 
patients with early onset of the disease show Mendelian transmission and are caused 
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by mutations in three genes, which are all involved in the production of Aβ (Tanzi and 
Bertram, 2005). The mutations affect the APP (Goate et al., 1991), presenilin 1 
(PSEN1; Sherrington et al.,1995) and presenlin 2 (PSEN 2; Levy-Lahad et al., 1995; 
Rogaev et al., 1995) genes, interfering with the normal cleavage of APP by the γ-
secretase complex.  
Overwhelming majority of AD patients exhibit the late onset of the disease and show 
less-obvious familial aggregation. Despite strong evidence of heritability (Bergem et 
al., 1997; Gatz et al., 2006), genetic mechanisms involved in late onset AD have 
been much more difficult to elucidate. The disease pathophysiology in these patients 
is most likely linked to a whole set of susceptibility genes affecting various pathways, 
as including those involved in Aβ production, such as SORL1, GAB2 or CH25H 
(Andersen et al., 2005; Zerbinatti et al., 2008), aggregation, such as CST3 or PRNP 
(Kaeser et al., 2007; Schwarze-Eicker et al., 2005), and clearance, such as ACE 
(Bertarm and Tanzi, 2009; Sleegers et al., 2010). The role of several other 
susceptibility genes has also been implicated in other pathophysiological pathways, 
such as TF, MAPT and GAB2 in oxidative stress (Yamamoto et al., 2002; Ballatore et 
al., 2007; Nizzari et al., 2007), CHRNB2 in Ach transmission (Oddo et al., 2006), CR1 
and CLU in inflammation damage (Khera and Das, 2009; Zanjani et al., 2005) or 
PICALM in intracellular trafficking of synaptic vesicle proteins (Harel et al., 2008). 
Over past several decades, more than 500 genes have been associated with 
increased risk of AD, mainly by utilizing the candidate-gene approach (Bertram and 
Tanzi, 2008).   
Despite the large number of candidate genes, only a few have been reproducibly 
shown to influence disease risk or onset age (Bertram et al., 2007). Among those 
genes, the ε4-allele of the apolipoprotein E gene (APOE) has shown the strongest 
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risk effect for the development of AD (Strittmatter et al., 1993; Saunders et al., 1993). 
APOE is found within senile plaques (Namba et al., 1991), binds Aβ (Strittmatter et 
al., 1993), may influence neuritic formation of plaques in mouse models of the 
disease (Holtzman et al., 2000) and is involved in Aβ deposition and clearance in the 
brain (Holtzman, 2004). Despite the strong evidence for its role in disease 
pathophysiology, APOE as a genetic risk factor is not fully penetrant, and is neither 
necessary not sufficient for the development of AD (Ertekin-Taner, 2010). 
Heterozygous carriers of the ε4 genotype exhibit a two to four times greater AD odds 
ratio when compared to homozygous ε3 carriers. In homozygous ε4 carriers the odds 
ratio increases to 6 to 30, as shown in population-based studies in subjects of 
European origins (Ertekin-Taner, 2007). However, the effect of APOE ε4 seems to be 
age dependent, and its use as a diagnostic and predictive factor in a clinical setting is 
not feasible (Knopman et al., 2001). 
Deciphering of the human genome and development of high-throughput genomic 
technologies (Manolio and Collins, 2009) have accelerated the efforts aimed 
unraveling of underlying pathophysiological mechanisms involved in AD. These 
achievements opened up to major avenues of scientific effort in research of AD. A 
new impetus was given to the search for candidate genes associated with increased 
risk of AD especially through performing genome-wide association studies (GWAS). 
In this review we give a comprehensive overview of the GWAS studies in AD 
performed so far, providing a novel overview of several GWAS approaches, from 
case-control studies, to copy number variations (CNV) analysis to quantitative-trait 
association studies. Furthermore, we also give emphasis on novel avenues of 
research, such as genome-wide analysis of CNV or low-frequency rare functional 
gene variants. 
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Genome-wide association studies in AD 
 
Detailed identification and characterization of single-nucleotide polymorphisms 
(SNPs) in the human genome (Sachidanandam et al., 2001) and development of 
novel high-throughput SNP genotyping technologies enabled a more comprehensive 
insight into the genetic basis of common, complex diseases. In contrast to candidate 
gene studies, which do not allow results beyond the scope of the initial hypothesis, 
GWAS allow for simultaneous testing of a very large number of genetic markers. The 
studies usually involve analysis of tens of thousands of genetic markers in thousands 
of individuals, in a mostly hypothesis-free manner (Betram and Tanzi, 2009). The 
genetic markers utilized in the GWAS consist of SNPs chosen based on their ability 
to cover common variation in the human genome (McCarthy et al., 2008). More 
recent microarray technology also allows for assessment of CNVs, namely deletions 
or multiplications of genomic DNA at certain chromosomal regions. 
 
Implementation of the GWAS approach has yielded a large number of genome-wide 
significant and replicated findings in many genetically complex diseases (Ioannidis et 
al., 2009). However it has been shown that most common variants individually or in 
combination confer relatively small increments in risk (1.1-1.5-fold) and explain only a 
small proportion of heritability (Hindorff et al., 2010). GWAS in AD have so far yielded 
much less reproducible results, when compared to studies of other complex 
diseases, with the exception of the APOE locus, whose association with AD was 
identified in all but one study, and always found to be orders of magnitude more 
significant than any of the newly implicated genes to date (Bertram and Tanzi, 2009). 
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Collective data overview and systematic meta-analysis of the association studies 
carried out in AD can be found at the AlzGene website. AlzGene represents the most 
comprehensive electronic database of the genetic association studies published in 
the field of AD, including GWAS (Bertram et al., 2007). The overview of the late onset 
AD GWAS results can be found in the Table 1. 
 
The study of Grupe et al. 2007 
The first published GWAS of late onset AD used a select set of more than 17,000 
SNPs from 11,211 genes, chosen according to likelihood of being functional 
polymorphisms (Grupe et al., 2007). In the first stage of the study, genotyping was 
performed on a screening sample consisting of 380 AD cases and 396 control 
subjects from UK. Follow-up studies of the promising markers were performed in four 
independent cohorts from UK and USA, totaling more than 3000 subjects. Among the 
loci identified, APOE-related SNPs were the only ones to exhibit genome-wide 
significance. Besides APOE, 16 more loci were identified as nominally significant, 
namely ACAN, BCR, CTSS, EBF3, FAM63A, GALP, GWA_14q32.13, GWA_7p15.2, 
LMNA, LOC651924, MYH13, PCK1, PGBD1, TNK1, TRAK1 and UBD. Although 
none of these replicated in more than two of the five tested samples groups, four 
SNPs were especially interesting, namely GALP, TNK1, PCK1 and GWA_14q32.13, 
exhibiting significant p-values across all samples. Subsequent replication studies 
have shown mixed results regarding confirmation of the identified loci, with 
GWA_14q32.13, TNK1 and GALP showing the strongest association. Galanine and 
galanine-like peptides (GALP) have been implicated in inhibition of long term 
potentiation in the hippocampus, as well in suppression of cholinergic 
neurotransmission (Lang et al., 2007), and have been shown to be overexpressed in 
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the AD brains. On the other hand, tyrosine kinase, non receptor 1 (TNK1) has been 
shown to enable tumor necrosis factor α induced necrosis, providing a possible 
mechanisms for increased neuronal death in AD patients. 
 
The studies of Coon et al. 2007 & Reiman et al. 2007 
The second study utilized the approach of genotyping more than 500,000 SNPS on 
the Affymetrix 500K platform (Coon et al., 2007). The analysis was performed on a 
sample of 664 neuropathologically confirmed AD cases and 422 controls from the 
US. Initial analysis showed that APOE was the only signal to reach genome-wide 
significance after Bonferroni correction for multiple testing. In an effort to identify 
additional statistically significant data, the authors focused on 312,316 SNPs and 
divided the neuropathological sample into discovery (736 combined cases and 
controls) and replication (321 subjects) cohort (Reiman et al., 2007). This was 
augmented with an additional group of 364 AD cases and controls with clinical 
diagnoses. Additionally, stratification on APOE ε4 genotype was performed. The 
analysis revealed genome-wide significant association with five SNPs in the GAB2 
gene. Follow-up studies have shown relative consistency regarding the role of GAB2 
in AD pathophysiology. GRB2-associated binding protein 2 (GAB2) is expressed at 
particularly high levels in the prefrontal cortex and the hypothalamus. The growth 
factor receptor bound protein (GRB2), which binds GAB2, has been proposed to 
regulate signal transduction and is thought to influence phosphorylation of tau. 
 
The study of Li et al. 2007 
A subsequent study analyzed more than 400,000 SNPs from the Affymetrix 500K 
platform using 753 AD cases and 736 controls of northern European ancestry from 
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Canada (Li et al., 2007). Statistically most significant signals were followed up in the 
418 AD cases and 249 control subjects. Once again, markers linked to APOE ε4 
exhibited genome-wide association with statistical significance. In addition, four SNPs 
showed consistent evidence of association in both investigated sample groups, 
although none with genome-wide significance. Two of the aforementioned SNPs 
reside in the GOLM1 gene (also known as GOLPH2), which is involved in Golgi 
transmembrane trafficking. Together with a SNP located in an uncharacterized region 
on chromosome 9 (GWA_9p24.3), they showed association with risk of AD. The 
remaining identified SNP in an uncharacterized region on chromosome 15 
(GWA_15q21.2) showed the strongest association with age of onset for AD. 
 
The study of Abraham et al. 2008 
Using a pooled DNA approach on 1082 AD cases and 1239 controls of Caucasian 
ancestry from UK, Abraham and coworkers tested the association of more than 
560,000 Hap-Map-based SNPs on two Illumina platforms (Abraham et al., 2008). 
Additionally, in the follow-up stage of the study the authors used previously published 
“general disease” controls from the Wellcome Trust Case-Control Consortium as 
additional control subjects. In addition to five APOE-related SNPs, 109 nominally 
significant results in other loci have also been discovered. Among the nominally 
significant loci, SNP rs727153, residing in the haplotype block on chromosome 4q32 
which includes the LRAT gene, showed the highest statistical significance. Due to the 
DNA polling approach and lack of independent case group in the follow-up stage, the 
results of the study still remain to be confirmed. 
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The study of Bertram et al. 2008 
The first study to employ the family-based methods for the initial screening and 
replicant analyses utilized the Affymetrix 500K SNP platform to analyze 941 AD 
cases and 404 controls from 410 families of European descent (Bertram et al., 2008). 
Follow-up analyses were performed in 1767 AD cases compared to 838 controls from 
three independent collections consisting of 875 families, also of European descent. 
The authors used a novel family-based association approach that assesses disease 
status and age of onset jointly. Opting for a non-traditional approach to data analysis, 
the authors of the study first screened all of the markers to estimate the conditional 
power of each marker. In the second step, they computed statistical significance for 
family-based association corrected according to weights derived from the initial 
analysis. In concordance with other GWAS findings, the most significant association 
was observed with a marker in strong linkage disequilibrium (LD) with APOE ε4. In 
addition, four non APOE SNPs where detected, none of which were previously 
described as potential modifiers of AD risk or onset age. Three of these markers 
exhibited significant (GWA_14q31.2, CD33), or at least marginally significant 
(ATXN1) association in the follow-up experiments as well. It is important to note that 
GWA_14q31.2 also showed consistent replication in one of the two publicly available 
GWAS datasets. 
 
The study of Beecham et al. 2009 
One of the more recent GWAS studies performed on late onset AD patients involved 
492 AD cases and 496 controls of Caucasian ancestry from the USA (Beecham et 
al., 2009). Promising signals were analyzed in a follow-up study involving 458 
independent subjects. All of the samples were analyzed using the Illumina HapMap 
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550 platform Additional confirmation was performed by imputing the genotype of the 
previously published GWAS data (Reiman et al., 2007). Besides the APOE-related 
genetic markers, the second most significant signal was associated to SNP in the 
FAM113B gene on the chromosome 12q13. The aforementioned signal retained 
nominal significance after confirmation in the follow-up sample, but fell short of 
achieving significance in the imputed dataset. Additionally, it has not been validated 
in any subsequent association study. Four additional signals showed consistent 
evidence of association across both studies, namely DISC1, ZNF224, and two loci on 
chromosomes 4q28 and 6q14. The authors also undertook to reanalyze both GWAS 
datasets in an effort to assess the association of the genes included in the AlzGene 
database. The analysis revealed nominal evidence of association with a total of eight 
loci. 
 
The study of Feulner et al. 2009 
Using only a single-stage GWAS approach, Feulner and co-workers analyzed 491 
AD cases and 479 younger controls from Germany, and focused on the top 10 genes 
included in the AlzGene database at the time of the study, as well as SORL1 
(Feulner et al., 2009). Following the analysis on the Illumina HapMap550 
microarrays, signals in 8 out of the 11 genes assayed revealed nominal significance 
of P<0.05 (GAB2, CHRNB2, CH25H, PGBD1, LMNA, PCK1, MAPT and SORL1). It 
is important to note that the study provided evidence of strong association at the 
extended APOE locus, particularly in the TOMM40 gene. 
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The study of Poduslo et al. 2009 
The second study to utilize the family-based approach studied a total of nine affected 
and 10 unaffected individuals from France belonging to two large, multiplex AD 
pedigrees versus 60 unrelated controls from the Centre d'Etude du Polymorphisme 
Humain collection (Poduslo et al., 2009). Using the Affymetrix 500K SNP 
microarrays, the authors reported a single genome-wide significant association with 6 
SNPs in the TRPC4AP gene. Interestingly, no association was reported for markers 
within or in LD with APOE. In an additional analysis, the authors identified a common 
10-SMP haplotype in the TRPC4APwith increased frequency in the AD patients from 
the families compared with the control spouses. In the follow-up study on 199 AD 
cases and 85 controls, the same haplotype showed nominal significance. Transient 
receptor potential cation channel, subfamily C, member 4 associated protein 
(TRPC4A) has been implicated in regulation of the inflammatory cascade and 
calcium homeostasis. It is important to note that due to the small samples size, initial 
comparison of AD cases versus unrelated controls and inability to prove association 
with APOE-related SNPs, the results of the study require further independent 
confirmation. 
 
The study of Carrasquillo et al. 2009 
In one of the largest AD GWAS studies published to date, Carrasquillo and co-
workers analyzed 844 late onset AD cases and 1255 controls from the US using the 
Illumina microarrays containing 300,000 HapMap-based SNPs (Carrasquillo et al., 
2009). The only signals to exhibit genome-wide significance in this first stage of the 
study were located on chromosome 19 and showed strong LD with APOE ε4. In a 
follow-up study conducted using 1547 AD cases and 1209 controls, the authors 
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analyzed the top 25 SNPs, 10 of which were in LD with APOE. Using the combined 
dataset, the authors described one marker in the PCDH11X gene in the 
pseudoautosomal region of chromosome X. In concordance with this finding, the 
association was strongest in females, with OR estimates of 1.26 for heterozygotes 
and 1.75 for homozygotes, versus non-carriers of the putative risk allele. Male 
hemizygotes showed a similar trend, with OR of 1.18, although not at statistically 
significant level (P=0.07). Protocadherins are known to be involved in cell-cell 
adhesion and signaling, as well as neural development. Additionally, some 
protocadherins have been proposed as γ-secretase substrates, possibly competing 
with APP (Haas et al., 2005). 
 
The study of Harold et al. 2009 
Most recent studies published in the last two years have used either increased 
numbers of case and control subjects, or have employed novel analysis methods, 
such as assessing the CNV or association of specific quantitative traits and 
endophenotypes in AD patients. 
Using 3941 late onset AD cases and 7848 controls from 13 different centers in 
Europe and US, Harold and coauthors analyzed association of more than 500,000 
SNPs on Illumina microarrays (Harold et al., 2009). Besides APOE-related markers, 
rs11136000 in CLU and rs3851179 in PICALM exhibited genome-wide significance. 
Follow-up study of 2023 AD cases and 2340 controls confirmed nominal significance 
for the two non-APOE signals. Additional SNPs, such as CR1, showed P values of 
less than 10E-5, and among the 100 SNPs previously reported in GWAS studies to 
confer risk for AD, the authors were able to confirm PCDH11X and SORL1 at a P 
value of less than 0.05. 
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The studies of Lambert et al. 2009 and Lambert et al. 2010 
Another large GWAS analyzed more than 500,000 SNPs in 2032 AD cases and 5328 
controls from France using the Illumina Human 610-Quad microarray (Lambert et al., 
2009). The first stage of the study revealed genome-wide significance of the 
rs11136000 marker in the CLU gene, in addition to the APOE-related markers. The 
significance of those SNPs was confirmed in the follow-up studies on 3978 AD cases 
and 3297 controls and in the combined series. In addition, a marker in the CR1 gene 
also achieved genome-wide significance in the combined series, while SNPs in 
PICALM and PCDH11X exhibited nominal significance. Clusterin (CLU) has been 
implicated in Aβ clearance from the brain and it has been proposed that it plays a 
role in Aβ fibrillogenesis and neurotoxicity (Holtzman, 2004). In a follow-up study, 
using the same dataset the authors utilized a different approach in analysis of the 
most significant associations by employing the two different gene set enrichment 
approaches and looking at the significantly associated groups of genes, rather than 
at individual genes (Lambert et al., 2010). The authors analyzed a large cohort of 
2032 AD cases and 5328 controls of European ancestry using the Illumina Human 
610-Quad Bead-Chips. After initial data filtering, the authors utilized the ALIGATOR 
software, developed to test over-representation of biological pathways in lists of 
significant SNPs from GWAS. They also performed the pathway based genome-wide 
association tests on SNP genotyping data with respect to the KEGG database. The 
results indicated 4776 SNPs nominally associated with risk of AD, which were 
assigned to 1395 genes involved in 173 KEGG pathways. Following the FDR 
correction, 5 physiological and disease-related KEGG pathways displayed significant 
over-representation of genes associated with the risk of AD. These included 
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pathways entitled AD, Regulation of autophagy, Natural killer cell mediated 
cytotoxicity, Antigen processing and presentation and RIG-I-like receptor signaling. 
The collective results of the study imply a strong role for and immune system 
dysfunction as a genetic risk for development of AD. 
 
The study of Seshadri et al. 2010 
In a recent effort to detect additional loci associated with AD, Seshadri and coworkers 
performed a 3-stage meta-analysis of new and previously published GWAS data on 
more than 35000 subjects of European ancestry, of which 8371 were AD cases 
(Seshadri et al., 2010). In stage 1 the authors performed a meta-analysis combining 
new genome-wide association data from Caucasian subjects which were part of the 
population-based Cohort for Heart and Aging Research in Genomics Epidemiology 
(CHARGE) consortium (Psaty et al., 2009) with GWAS data from the previous 
publications by Reiman and coworkers (2007) and Carrasquillo and coworkers 
(2009). The samples consisted of 8935 dementia-free individuals, of whom 973 
developed incident AD over an average follow-up time of 8 years, and 2033 prevalent 
cases of AD who were compared to 14642 dementia-free controls. The analysis 
yielded 2078 SNPs with P<10-3, which were subsequently studied in stage 2. After 
pooling the results for the aforementioned SNPs with the subjects from European AD 
Initiative (Lambert et al., 2009), in stage 2 of the study the authors were able to 
identify 38 SNPs corresponding to 10 loci with P<10-5. The sample consisted of 2032 
cases and 5328 controls.  Finally, in stage 3 of the study, top SNPs from the 10 loci 
were meta-analyzed with the non-overlapping studies from Genetic and 
Environmental Risk in AD consortium (Harold et al., 2009) consisting of 3333 AD 
cases and 6995 controls. The final results in the Stage 3 of the study showed 
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genome-wide significance for 4 SNPs with P<1.7x10-8 in addition to APOE-related 
markers. These included CLU and PICALM, as well as two novel loci on 
chromosome 2 and 19. The locus 2q14.3 is adjacent to the BIN1 gene, which is 1 of 
2 amphiphysins and is expressed most abundantly in the brain and muscle 
(Wechsler-Reya et al., 1997). It has also been implicated in promotion of caspase-
independent apoptosis and plays a role in neuronal membrane organization and 
vesicle trafficking (Wigge et al., 1997). The other locus 19q13.3 is adjacent to 6 
genes, 2 of which are part of pathways linked to AD pathology. The genes in 
question are BLOC1S3, which has already been implicated in schizophrenia (Morris 
et al., 2008), and MARK4, which plays a role in neuronal differentiation (Moroni et al., 
2006). The 4 associations were also replicated in an independent sample of Spanish 
origin, consisting of 1140 AD cases and 1209 controls (Antunez et al., 2009). The 
authors tried to assess whether APOE ε4, PICALM and CLU can improve predictive 
models for risk of incident AD in general population, but the findings showed that the 
predictive ability of the assayed genes was not clinically significant. The study 
represents an important milestone in AD research since it included the largest 
sample of clinic- and community-based cases and controls. However, the study 
showed limited power in detecting associations with small effect sizes and 
associations with rare variants. 
 
The study of Naj et al.  2010 
Expanding on the initial findings from the study published by Beecham and co-
authors (Beecham et al., 2009), the authors conducted a follow-up GWAS by 
combining the initial 492 AD cases and 496 controls with an independent set of 439 
AD cases and 608 controls of European ancestry (Naj et al., 2010). The new cohort 
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was analyzed in an effort to strengthen the power to identify novel genetic 
association signals. The most significant findings were replicated in an additional 
cohort containing 1338 cases and 2003 controls. As previously reported, APOE 
related SNP rs2075650 showed the most significant association with AD risk 
(p=1.9x10-36). Among other significantly associated SNPs rs11754661 located in the 
MTHFD1L gene also showed significant association with AD (p=4.7x10-8). The gene 
which encodes methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 
protein is involved in tetrahydrofolate (THF) synthesis, which is an important step in 
homocysteine conversion to methionine. Elevated levels of homocysteine have been 
implicated in AD (Morris, 2003; Van Dam and Van Gool, 2010) and other 
neurodegenerative diseases (Herrmann and Knapp, 2002). It is important to note that 
association of MTHFD1L represents a novel finding for a genetic risk factor 
associated with AD, with viable biological and functional justification. 
 
 
Copy number variation analysis in AD 
The study of Heinzen et al. 2010 
A growing number of studies have suggested that structural variation, including 
CNVs, may contribute to human disease (Estivill and Armengol, 2007) and a rare 
duplication of APP has already been linked to early onset AD. Using 331 AD cases 
and 368 controls of European ancestry, the authors conducted genome-wide 
genotyping on Illumina Human HapMap550K microarrays (Heinzen et al., 2010). 
GWAS results showed that only one SNP in the TOMM40 gene, located upstream of 
APOE ε4 gene, achieved genome-wide significance. The authors also evaluated 
previously reported genome-wide significant associations as well as 21 genes 
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implicated in candidate gene studies, but found no significant associations within 
their data set. The authors also preformed assessment of CNVs and, although they 
showed no clear excess of large deletions or multiplications, duplication within the 
schizophrenia and epilepsy associated risk region at 15q13.3 affecting the CHRNA7 
gene was found in 2% of AD cases and 0.3% of control subjects. Additional analyses 
are required to fully assess the impact of rare structural variants in AD. 
 
 
Quantitative-trait association studies in AD 
The study of Potkin et al. 2009 
Trying to apply quantitative trait association approach, Potkin and coworkers 
combined the neuroimaging data of hippocampal gray matter density MR 
measurements with results of the Illumina Human610 Quad microarray genotyping 
(Potkin et al., 2009). The study consisted of 172 AD cases and 209 controls of 
European ancestry from the Alzheimer's Disease Neuroimaging Inititative study. In 
the first part of the study, the authors performed a standard case-control study, which 
confirmed the association with APOE-related loci and also implicated TOMM40, a 
gene physically close to APOE, previously shown to exhibit significant association to 
AD. Application of the QT analysis identified additional 21 genes or chromosomal 
areas with at least one SNP with P<10-6. The candidate genes included EFNA5, 
CAND1, MAGI2, ARSB and PRUNE2 genes, which have been implicated in 
ubiquination, oxidative necrosis, hippocampal development and dementia. The QT 
association studies offer a more objective measure compared to diagnostic 
categorization of case-control studies and can greatly increase statistical power of 
the findings. However, it should be emphasized that the authors analyzed only a 
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small number of mild AD patients, which are not fully representative of the disease. 
Additionally, selection of suitable quantitative traits in a complex disease as AD may 
prove to be a challenge. 
 
The study of Stein et al 2010. 
Using a similar approach, Stein and coauthors compared 3D profiles of temporal 
volume in MRI brain scans of AD patients, mildly impaired and healthy elderly 
subjects of European ancestry to genotyping data analyzed using the Human610-
Quad microarrays (Stein et al., 2010). The study consisted of 173 AD cases, 361 MCI 
subjects and 208 control subjects. The results indicated two SNPs with genome-wide 
significance, namely rs10845840 (P=1.260x10-7) located in chromosome 12 within an 
intron of the GRIN2B gene and rs 2456930 (P=3.142x10-7), which lies in an 
intergenic region of chromosome 15. GRNB2 encodes the NR2B subunit of the 
NMDA receptor and is involved in learning and memory, structural plasticity of the 
brain, as well as neurodegeneration. Additional genes with nominal significance of 
P<10-5 were also identified, and included RNF220, UTP20 and KIAA0743. 
 
The study of Biffi et al. 2010 
Another study utilizing the available genotyping and neuroimaging data from the 
Alzheimer’s Disease Neuroimaging Initiative tried to assess the association of 
GWAS-validated and GWAS-promising novel AD loci on hippocampal volume, 
amygdale volume, white matter lesion volume (WML), entorhinal cortex thickness 
(ECT), parahippocampal gyrus thickness and temporal pole cortex thickness (TPT) 
(Biffi et al., 2010). The study included a total of 168 individuals with probable AD, 357 
with MCI and 215 cognitively normal control individuals of European ancestry, who 
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have not been analyzed in previous association studies. The strongest association 
with clinical diagnosis was shown by APOE, while of the previously confirmed non-
APOE AD loci, only CR1 was replicated in the data set with SNP rs1408077 showing 
a significant association (OR 1.27, FDR-corrected P=0.02). Novel AD associated 
variants included CNTN5 and BIN1. Using a genetic risk score analysis including 5 
SNPs representing CLU, PICALM, CR1, CNTN5 and BIN1, the authors showed that 
predictive performance between score-based analysis and individual SNP analyses 
favored the cumulative effects model. As far as the correlation of genetic variants to 
the MR measurements is concerned, the results showed strong association of the 
APOE allele to all measures except WML. Further analyses showed association of 
GWAS-validated SNPs rs1408077 at CR1 with ECT and rs3851179 at PICALM with 
hippocampal coulume and ECT. Furthermore, novel associations were found for 
rs1501927 at CNTN5 with WML volume, parahippocampal gyrus thickness, TPT and 
ECT, as well as rs7561528 at BIN1 with TPT and ECT. 
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Discussion 
Despite considerable advances in our understanding of genetic mechanisms involved 
in development of AD brought about by application of powerful high-throughput 
genome-wide association studies, full elucidation of the genetic disease risk factors is 
still evading scientists working in the field. In this review we have described results of 
eighteen studies utilizing different approaches to assess genome-wide association 
significance, varying from traditional case-control GWAS studies, to CNV analysis to 
quantitative-trait association studies. Collectively, the studies resulted in a large 
number of potentially interesting candidate genes. However, additional confirmation 
of the results is needed, not only through further association studies on larger 
samples of ethnically diverse subjects, but also on a functional level.  
As is the case with many other genetically heterogeneous and complex diseases, the 
results show that the susceptibility genes confer relatively small increments in risk 
and a large number of common genetic variants may be required to account for the 
genetic risk in AD. However, the majority of the heritable component of the disease 
remains still largely unexplained. Therefore, to fully understand the genetic 
background of a given disease or trait, we must first understand the basis for this 
missing heritability (Gandhi and Wood, 2010). The missing heritability could be 
explained in several ways. Firstly, the majority of the genetic burden could be caused 
by independent factors of small effect size acting cumulatively to cause the disease. 
Secondly, the missing heritability might be explained by concerted action of multiple 
genes in an inter-dependent manner, through a, so far, unidentified pathway. Lastly, 
the burden might be the result of rarely occurring highly penetrant mutations.  
This approach of searching for rare causal variants, described as having a minor 
allele frequency of less than 1%, each of modest effect, but residing within the same 
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functional unit, for example a gene (Morris and Zeggini, 2010), holds great promise. 
The aggregate role of low-frequency rare functional gene variants has not been 
properly evaluated in AD to date. These uncommon variants with relatively large 
effects might account for part of the unexplained heritability in AD. To establish the 
associations with rare variants it is necessary to perform direct mapping and rare 
variants within a sample must first be identified. The optimal way to identify rare 
variants is either through sequencing of candidate genes or large-scale sequencing 
of the entire genome. It is hypothesized that rare variants are more likely to be 
functional than common variants, which lead to an emerging interest in association 
studies of rare variants (Li and Leal, 2009). The completion of the 1,000 Genomes 
Project (Siva , 2008), which will perform whole genome re-sequencing of at least 
1,000 genomes from 10 different ethnic backgrounds, and similar efforts are poised 
to shed much needed insight into the role of rare variants in pathophysiology of 
complex diseases.  
Another crucial step in the fine-tuning of the initial GWAS results would include 
assessment of gene/gene and gene /environment interactions. These evaluations will 
present a substantial effort, since they require advanced computational methods and 
precise measurement of both the phenotype and the environmental factors. These 
efforts could help better understand the influence of environmental factors which 
could enhance disease onset, as well as disease progression (Manolio et al., 2009). 
Functional follow-up studies are a critical step in any observation stemming from an 
association study, conveying biological relevance to a possible genetic risk factor. 
Establishing the functional effect of a genetic factor is demanding, and includes 
numerous avenues of endeavor. These include employing similar approaches as in 
studying Mendelian genes, namely through generation of knock-in and knockout 
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animal models, and studying the effect of the loss-of-function or gain-of-function on 
the organism. Another approach may be to attempt to model the predicted genomic 
effect of any variant. However, these approaches are demanding, since the genomic 
effect of the causal variant is quite often unknown (Gandhi and Wood, 2010). 
It is also important to note that most of the GWAS experiments have been conducted 
using individuals of European ancestry. Recent studies have indicated that genome-
wide studies in a diverse set of population samples can offer improved power for 
discovery of causal genetic variants as compared to a study focusing exclusively on 
European population samples. The observed effect is dominated by the alleles found 
in lower frequency in populations of European-ancestry. The findings indicate that 
future GWAS and re-sequencing experiments could benefit greatly from inclusion of 
diverse population samples (Pulit et al., 2010). 
One possible approach could be further study of CNVs across the genome in patients 
with AD. It is a well known fact that genomic structural variations are an important 
source of genetic variation and that they may increase the risk for a number of 
multifactorial diseases (Redon et al., 2006). Studies such as the one performed by 
Heinzen and coworkers (Heinzen et al., 2010) show promise in applying such 
approaches in the study of AD genetics. However, recent studies performed on large 
cohorts of patients with common complex diseases (Craddock et al., 2010), show 
that using common CNVs in association studies may not be as straightforward as 
previously imagined. 
Finally, comparing GWAS to results of other omics approaches, such as expression 
profiling or proteomic analyses, may prove beneficial especially when predicting the 
genetic risk conveyed by the causal variants. Such prediction programs, aimed at 
determining susceptibility to AD, may prove helpful in the future as part of a 
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diagnostic algorithm or as a means of identifying high-risk individuals. Such 
approaches might provide an important step from association results to identification 
of biologically relevant causal variants and potential new diagnostic and therapeutic 
algorithms. 
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Table 1. Summary of the results of genome-wide association studies in AD 
Study Type Platform Genes 
Grupe et al., 2007. GWAS       
case-control 
Celera SNP 
platform 
APOE, ACAN, BCR, CTSS, EBF3, 
FAM63A, GALP, GWA_14q32.13, 
GWA_7p15.2, LMNA, LOC651924, 
MYH13, PCK1, PGBD1, TNK1, 
TRAK1, UBD 
Coon et al., 2007. GWAS       
case-control 
Affymetrix 500K APOE 
Reiman et al., 2007. GWAS       
case-control 
Affymetrix 500K APOE, GAB2 
Li et al., 2008. GWAS       
case-control 
Affymetrix 500K APOE, GOLM1, GWA_9p24.3, 
GWA_15q21.2 
Abraham et al., 2008. GWAS       
case-control 
Affymetrix 500K APOE, LRAT 
Bertram et al., 2008. GWAS      
family-based 
Affymetrix 500K APOE, ATXN1, CD33, 
GWA_14q31.2 
Beecham et al., 2009. GWAS       
case-control 
Illumina HapMap 
550K 
APOE, FAM113B 
Feulner et al., 2009. GWAS       
case-control 
Illumina HapMap 
550K 
APOE/TOMM40 
Poduslo et al., 2009. GWAS       
case-control 
/family-based 
Affymetrix 500K TRPC4AP 
Carasquillo et al., 2009. GWAS       
case-control 
Illumina HapMap 
300K 
APOE, PCDH11X 
Harold et al., 2009. GWAS       
case-control 
Illumina HapMap 
300/550K  
Illumina 610-quad 
APOE, CLU, PICALM 
Lambert et al., 2009. GWAS       
case-control 
Illumina 610-quad APOE, CLU, CR1 
Heinzen et al., 2009. GWAS/CNV      
case-control 
Illumina HapMap 
550K 
APOE/TOMM40, CHRNA7 
Potkin et al., 2009. GWAS/QT-AS 
case-control 
Illumina 610-quad APOE/TOMM40, EFNA5, CAND1, 
MAGI2, ARSB, PRUNE2 
Naj et al., 2010. GWAS       
case-control 
Illumina 610-quad 
Illumine 1M 
APOE/TOMM40, MTHFD1L, 
PVRL2, RDH13, GRIA4 
Seshadri et al., 2010. GWAS       
case-control 
Affymetrix & 
Illumina various 
APOE, CLU, PICALM, 
GWA_2q14.3, GWA_19q13.3 
Stein et al., 2010. QT-AS       
case-control 
Illumina 610-quad GRIN2B, GWA_15q22.2 
Biffi et a., 2010. QT-AS       
case-control 
Illumina 610-quad APOE,CR1, CNTN5, BIN1 
 
